Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Allyson Price, MPAS, PA-C
J Adv Pract Oncol 2021;12(suppl 1):10-11 |
© 2021 Harborside™
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, highlights implications for advanced practitioners from the presentation at the 2020 SOHO Annual Meeting by Guillermo Garcia-Manero, MD, also from MD Anderson Cancer Center, on the development of oral hypomethylating agents for myelodysplastic syndromes.
For access to the full length article, please sign in